Glucose transporter 1 in rheumatoid arthritis and autoimmunity.
Ekaterina ZezinaOezen Sercan-AlpMatthias HerrmannNadine BiesemannPublished in: Wiley interdisciplinary reviews. Systems biology and medicine (2020)
Knowledge about metabolism of immune cells increased almost exponentially during the last two decades and thereby created the new area immunometabolism. Increased glucose uptake and glycolysis were identified as one of the major drivers in immune cells for rapid adaptation to changes in the microenvironment or external stimuli. These metabolic switches are crucial to generate macromolecules for immune cell proliferation and activation. Glucose transporter 1 (GLUT1), a ubiquitously expressed glucose transporter, is strongly upregulated after innate and adaptive immune cell activation. Deletion or inhibition of GLUT1 blocked T cell proliferation and effector function, antibody production from B cells and reduced inflammatory responses in macrophages. Increased glucose uptake and GLUT1 expression are not only observed in proinflammatory conditions, but also in murine models of autoimmunity as well as in human patients. Rheumatoid arthritis (RA), the most common autoimmune disease, is characterized by infiltration of immune cells, hyperproliferation of fibroblast-like synoviocytes, and destruction of cartilage and bone. These processes create a hypoxic microenvironment in the synovium. Moreover, synovial samples including fibroblast-like synoviocytes from RA patients showed increased lactate level and upregulate GLUT1. Similar upregulation of GLUT1 is observed in systemic lupus erythematosus and psoriasis patients as well as in murine autoimmune models. Inhibition of GLUT1 using either T cell specific knockouts or small molecule GLUT1/glycolysis inhibitors improved phenotypes of different murine autoimmune disease models like arthritis, lupus, and psoriasis. Thereby the therapeutic potential of immunometabolism and especially interference with glycolysis was proven. This article is categorized under: Biological Mechanisms > Metabolism Translational, Genomic, and Systems Medicine > Translational Medicine Physiology > Mammalian Physiology in Health and Disease.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- cell proliferation
- newly diagnosed
- small molecule
- chronic kidney disease
- ejection fraction
- peritoneal dialysis
- disease activity
- multiple sclerosis
- blood glucose
- prognostic factors
- stem cells
- systemic lupus erythematosus
- type diabetes
- endothelial cells
- cell cycle
- poor prognosis
- signaling pathway
- interstitial lung disease
- dna methylation
- risk assessment
- dendritic cells
- bone mineral density
- adipose tissue
- climate change
- metabolic syndrome
- atopic dermatitis
- ankylosing spondylitis
- insulin resistance
- soft tissue
- skeletal muscle
- sensitive detection
- body composition
- induced pluripotent stem cells
- patient reported
- celiac disease
- type iii